SELECTED ABSTRACTS FOR POSTER PRESENTATIONS
IN ALPHABETIC ORDER ACCORDING TO THE NAME OF THE FIRST AUTHOR
TRIALS IN PROGRESS
Poster 47: AN OPEN-LABEL, MULTICENTER, PHASE 3B STUDY TO ASSESS THE SAFETY
AND EFFICACY OF MIDOSTAURIN IN PATIENTS AGED ≥18 YEARS WITH
NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) WHO
ARE ELIGIBLE FOR 7+3 OR 5+2 CHEMOTHERAPY
Sejla Hodzic, Pilar Hernández, Ana Rita Ferriera and Geralyn Gilotti
SCIENTIFIC
PROGRAMME
RARE SUBSETS OF
ACUTE LEUKAEMIA
TRACKING LEUKAEMIC
STEM CELLS (LSCs)
ROUTINE DIAGNOSIS
GENE EXPRESSION
AND MUTATIONAL
PROFILING
DEBATE 1 – ALL
PATIENTS WITH
INTERMEDIATE-RISK
AML MUST BE
TRANSPLANTED
INTERACTIVE
CASES 1 – MUTATION-BASED
THERAPY
OFF-LABEL
ROUNDTABLE –
SHOULD WE REALLY
USE NEW TARGETED
INHIBITORS AS SINGLE
AGENTS ?
ADDITION OF A 3RD
AGENT TO FRONTLINE
7+3
ROUNDTABLE –
CURATIVE OPTIONS
FOR OLDER AML
INTERACTIVE CASES 2
DEBATE 2 - BEST
TREATMENT FOR
NPM1-MUTATED AML IN
THE NEXT FUTURE ?
ALLOGENEIC
HAEMATOPOIETIC
STEM CELL
TRANSPLANTATION
(HSCT)
IMMUNOTHERAPY FOR
ACUTE LEUKAEMIA
DEBATE 3 - T-ALL:
WHERE ARE WE GOING
NOW?
SELECTED ABSTRACTS
AND CLINICAL
CASES FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES